FDA
-
-
-
-
-
-
-
Longeveron stem cell therapy data to be presented at 2026 AAIC
-
-
-
-
-
-
-
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
-
-
-
-
-
-
-
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
-
-
-
-
-
-
-
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
-
-
-
-
-
-
-
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
-
-
-
-
-
-
-
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
-
-
-
-
-
-
-
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
-
326,872 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

